Roquefort Therapeutics (LON:ROQ) Trading Down 2.1% – What’s Next?

Roquefort Therapeutics plc (LON:ROQ)’s share price dropped 2.1% during trading on Thursday . The company traded as low as GBX 3.50 ($0.04) and last traded at GBX 3.77 ($0.05). Approximately 1,022,574 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 1,298,604 shares. The stock had previously closed at GBX 3.85 ($0.05).

Roquefort Therapeutics Price Performance

The company has a 50 day simple moving average of GBX 4.24 and a 200 day simple moving average of GBX 4.11. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock has a market cap of £4.68 million, a P/E ratio of -362.00 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.